Retraction Retraction dated 2022-11-29
Click to view Retraction: https://doi.org/10.1038/s41598-022-24707-3
Retraction Retraction dated 2022-11-29
Click to view Retraction: https://doi.org/10.1038/s41598-022-24707-3
Updates are available Expression of concern dated 2022-01-07
Click to view Expression of concern: https://doi.org/10.1038/s41598-021-93326-1
-
Authors
Woods, Kristina N.
-
Funding
Funding for this research was provided by:
OOO “NPF “MATERIA MEDICA HOLDING”,
Ludwig-Maximilians-Universität München
- License Information
-
More Information
Article History
Received: 1 March 2021
Accepted: 21 June 2021
First Online: 2 July 2021
Change Date: 7 January 2022
Change Type: Update
Change Details: Editor’s Note: Readers are alerted that the conclusions of this paper are subject to criticisms that are being considered by the Editors. Further editorial action will be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.
Change Date: 29 November 2022
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1038/s41598-022-24707-3
Competing interests
: The author declares the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: OOO “NPF “MATERIA MEDICA HOLDING” (Moscow, Russia) sponsored the study. Different technological versions of HD-anti- IFN-γ are the substances (single or one among other components) for commercial drugs produced or produced and marked by OOO “NPF “MATERIA MEDICA HOLDING”. All HD-samples tested in the study were prepared and provided by OOO “NPF “MATERIA MEDICA HOLDING”. Several patents on these substances belong to OOO “NPF “MATERIA MEDICA HOLDING”. The author has disclosed those interests fully to Scientific Reports.
